We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

YAG Laser Versus Punch Biopsy for the Treatment of Tattoo Skin Markers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00271674
First Posted: January 4, 2006
Last Update Posted: June 3, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
  Purpose
The purpose of the study is to compare patient satisfaction, clinical efficacy and adverse effects of Q-switched YAG laser versus punch biopsies for the treatment of tattoo dots that are applied as skin markers in relation to X-ray treatment of malignant disorders.

Condition Intervention
Tattoo Skin Markers Device: Q-switched YAG laser

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment

Further study details as provided by Bispebjerg Hospital:

Study Start Date: January 2006
Study Completion Date: December 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • 18 years or older,
  • Skin types I-IV,
  • No previous laser treatment for the condition.

Exclusion Criteria:

  • Younger than 18 years,
  • Skin types V-VI,
  • Pregnant or lactating women,
  • Previous laser treatment for the condition,
  • Recent exposure to sun or sun-beds,
  • Treatment with oral retinoids within 3 months,
  • Tendency to produce hypertrophic scars or keloids,
  • Immunosuppressive treatment or disorders
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271674


Locations
Denmark
Bispebjerg Hospital
Copenhagen, Copenhagen NV, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Principal Investigator: Merete Haedersdal, MD, PhD, DrMedSci. Bispebjerg Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00271674     History of Changes
Other Study ID Numbers: KF-01-275533
First Submitted: January 3, 2006
First Posted: January 4, 2006
Last Update Posted: June 3, 2008
Last Verified: June 2008